Rx License-Rx

20-9434-tpNCS

Engineered Wasp Venom for Safe and Effective Antibiotics

A method for manipulating wasp venom peptide to maintain antimicrobial properties while reducing human toxicity. Problem: Almost 20% of global deaths ( ~ 11 million) are from sepsis, often caused by bacterial infections. 35,000 of these deaths are due to drug-resistant bacteria, which are becoming more prevalent. Drug-resistant bacteria are also dangerous in secondary infections. These drug-resistant infections pose a large threat during global pandemics such as the current COVID-19 pandemic. Therefore, there is a need for new and effective antibiotics. Toxins contained in venom have antibiotic potential, however these venoms are inherently toxic to humans. Solution: Modified wasp venom peptide has potent antibacterial activity while avoiding the toxicity of normal wasp venom. The modified peptide also reduces inflammation while activating an effective immune response to bacterial infection. Inventors: Cesar de la Fuente-Nunez,...

Intelligence Memo

Owner: University of Pennsylvania

Core category: Therapeutics

Therapeutic area: Immunology

Indication: Sepsis

Modality: Biologic

Focus tags: Immunology, Inflammation, Infectious Disease

Technology tags: Biologic, Diagnostic / Biomarker

Mechanism:

Development stage: Preclinical

Patent status: US 12,116,387

Availability: Available for license

Plain-English Licensing Breakdown

This is a license opportunity for a therapeutic asset or drug-enabling technology in Immunology. In plain English, the buyer would be licensing science that could become a treatment program, usually after more validation. The current package appears to be preclinical and is associated with University of Pennsylvania. The practical first use case is Sepsis. Public description: A method for manipulating wasp venom peptide to maintain antimicrobial properties while reducing human toxicity. Problem: Almost 20% of global deaths ( ~ 11 million) are from sepsis, often caused by bacterial infections. 35,000 of these.

What is exciting

Already past pure discovery: Preclinical validation gives a buyer something concrete to reproduce, optimize, or package into an IND-enabling plan.

Can sell into pharma before reimbursement: A biomarker or AI tool can create value as trial enrichment, patient stratification, or translational support before becoming a regulated diagnostic.

The License-Rx pivot is the real unlock: The exciting version is not just the university pitch; it is the focused path: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch

Negatives / diligence concerns

Translation still unproven: Animal or lab data may not predict human performance; tox, PK/PD, CMC, and indication selection still need diligence.

Validation can be harder than the demo: Models and biomarkers need locked datasets, external validation, clinical utility, data rights, and a regulatory/reimbursement plan.

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Immunology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets GSK — Vaccines and anti-infective infrastructure. Pfizer — Hospital, anti-infective, and vaccine commercial reach. Johnson & Johnson — Pathogen-focused development and global health channels.

Development Strategy to Increase PoS

First indication: Sepsis

Study design: Retrospective locked-dataset validation followed by one prospective pharma enrichment pilot.

Key experiments Validate the AI-optimized pivot: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed: Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch

Best next experiment: Run the smallest independent study that validates: Run pathogen-panel susceptibility, resistance mapping, and one translational model before any broad tox spend.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.